Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career
Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi
GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso.
'We are thrilled to welcome Teri and Jerry to our Board as we move into late-stage clinical development for pemvidutide and begin preparing for the transition to a pre-commercial-stage organization,' said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. 'Teri's deep expertise leading large organizations and global portfolios in cardiovascular and metabolic diseases and other therapeutic areas coupled with Jerry's extensive leadership experience in biopharmaceutical commercialization and corporate strategy, particularly in liver disease, will be invaluable as we continue advancing the pemvidutide franchise. Teri and Jerry have overseen late-stage development, approvals and launches of multiple products during their distinguished careers. The breadth and depth of their executive and commercialization expertise will enhance our talented Board and will help guide the continued execution of our strategic vision to develop and commercialize pemvidutide.'
Teri Lawver is an accomplished healthcare executive with nearly 30 years of experience across the pharmaceutical, medical device and consumer health technology sectors. She most recently served as Executive Vice President and Chief Commercial Officer at Dexcom (Nasdaq: DXCM), where she led global commercial strategy and operations, including the launch of the industry's first over-the-counter glucose biosensor. Prior to Dexcom, she spent two decades at Johnson & Johnson in a series of senior leadership roles spanning strategy, commercialization and executive management, including serving as Global Vice President for Janssen's Cardiovascular & Metabolism therapeutic area and subsequently Worldwide Vice President for the Immunology business at Janssen Pharmaceuticals, where she had global commercial responsibility for Janssen's $16 billion immunology portfolio and pipeline. Earlier in her career, she was an Associate Principal at McKinsey & Company, advising Fortune 100 healthcare companies on strategy and optimizing commercial operations. Ms. Lawver holds an MBA from Duke University's Fuqua School of Business and a B.S. in linguistics from Georgetown University.
Ms. Lawver stated, 'It is an honor to join Altimmune's Board at such an exciting time in the Company's evolution. Pemvidutide has shown what I believe to be compelling direct liver effects plus robust weight loss with significant lipid reductions and preservation of lean muscle mass. I am excited to work alongside the other Board members and the leadership team to continue advancing pemvidutide toward a potential commercial launch.'
Jerry Durso brings over 30 years of results-oriented leadership experience in the life sciences industry, with expertise in corporate and commercial strategy and business operations. He most recently served as Chief Executive Officer and a member of the Board of Directors of Intercept Pharmaceuticals, where he built a successful rare liver disease franchise and ultimately led the company through its successful acquisition by Alfasigma. Prior to his time at Intercept, Mr. Durso spent over two decades at Sanofi, where he held multiple senior leadership positions, including Chief Commercial Officer of the Company's Global Diabetes Division, Chief Commercial Officer of its U.S. Pharmaceuticals business and Head of its U.S. Cardiovascular and Specialized Therapeutic Business Units. He holds a BBA in marketing from the University of Notre Dame.
Mr. Durso added, 'Pemvidutide is a very exciting product candidate that not only drives significant liver defatting, but also has been shown to promote clinically meaningful weight loss and improvements in serum lipids, potentially offering a benefit across a range of liver and metabolic diseases. I look forward to contributing my late-stage clinical and commercial experience to work with the Board and the management team to help bring pemvidutide to patients in need.'
About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Northern Trust Appointed Custodian for Dutch Pension Fund BPF Beton
AMSTERDAM--(BUSINESS WIRE)--Northern Trust (Nasdaq: NTRS) announced today that it has been appointed by Dutch pension fund BPF Beton to provide global custody, regulatory reporting, valuation and accounting, and performance analytics. BPF Beton is the industry pension fund for people working in the concrete products industry in the Netherlands with approximately EUR 1.2 billion (approximately US$1.2 billion) in assets as at 31 December 2024. Herman Prummel, country head, Netherlands, Northern Trust, said: 'We are pleased to be supporting BPF Beton. Northern Trust has been servicing Dutch pension clients for four decades and is a long-term strategic partner to the pensions industry. With our deep local market expertise, global scale, data and technology platform, Northern Trust is committed to the Dutch pensions industry and its evolving needs. This mandate showcases our regional commitment and expertise in ensuring a seamless, efficient transition to the new reporting standards. We look forward to working with BPF Beton and continuing to serve the needs of the Dutch pension fund industry.' The pension system in the Netherlands is migrating to a defined contribution system, known as the Future of Pensions Act or 'Wet Toekomst Pensioenen'. BPF Beton sought an asset servicing partner that could help them through the changes brought on by the new legislation. Govert van der Peijl, president and chairman of BPF Beton, said: 'This transition is complex and large scale. We sought a strategic service provider who understands the requirements under the new legislation and who can support us navigate this new landscape. Northern Trust impressed us with their rapid response to the new legislation and their dedication to the Dutch pension fund industry. We are pleased to collaborate with Northern Trust and look forward to their support as our scheme embarks on the next chapter of its journey to deliver the best possible outcomes for our members.' About BPF Beton BPF Beton is the sectoral pension scheme for employees active in the manufacturing industry for concrete products. Based in Amsterdam, they represent over 25,000 members as at 31 December 2024. About Northern Trust Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 24 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of March 31, 2025, Northern Trust had assets under custody/administration of US$16.9 trillion, and assets under management of US$1.6 trillion. For more than 135 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit us on Follow us on Instagram @northerntrustcompany or Northern Trust on LinkedIn. Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at
Yahoo
an hour ago
- Yahoo
Billionaire Bill Ackman Wants to Be the Next Warren Buffett, and He Is Buying an AI Stock Up 855% in 10 Years (Hint: Not Nvidia)
Billionaire Bill Ackman will turn Howard Hughes Holdings into a modern-day Berkshire Hathaway in an effort to recreate Warren Buffett's success. Ackman's hedge fund Pershing Square Capital Management recently took a stake in Amazon, an artificial intelligence stock up 855% in the last decade. Amazon has three major growth opportunities in e-commerce, digital advertising, and cloud computing, and the company is using AI to boost revenue and improve margins. 10 stocks we like better than Amazon › In 1965, Warren Buffett took control of Berkshire Hathaway. He said that in hindsight it was a "doomed" textile mill "headed for extinction." But he saved the business, and laid the foundation for lasting growth, by shifting its focus to insurance. That brilliant decision created a steady inflow of investable capital in the form of insurance premiums, and Buffett used that cash to great effect over the years. Berkshire's market value has increased more than 5,500,000% since Buffett took control, for an average annual return of 20% over six decades. Buffett deserves much of the credit. He (along with the late Charlie Munger) engineered acquisitions, stock purchases, and share buybacks that ultimately turned Berkshire into a trillion-dollar business, one of only 11 in the world at this writing. While Buffett plans to step down as chief executive at Berkshire this year, billionaire Bill Ackman hopes to recreate his success with Howard Hughes Holdings. Ackman recently added another 900 million shares to his hedge fund, bringing his total ownership to 46.9%. He plans to turn Howard Hughes into a "modern-day version of Berkshire" by acquiring controlling interests in private and public companies. If Ackman succeeds, he could become the "next Warren Buffett." Here's the artificial intelligence stock he just bought. Bill Ackman ranks among the 20 most successful hedge-fund managers as measured by net gains, according to LCH Investments. And Pershing Square outperformed the S&P 500 (SNPINDEX: ^GSPC) by 24 percentage points over the last five years. Those accomplishments make Ackman an excellent source of inspiration. Importantly, he purchased three stocks during the first quarter: Hertz Global, Uber Technologies, and Brookfield Corporation. Those trades were disclosed in a Form 13F filed last month, but Pershing more recently added Amazon (NASDAQ: AMZN), an artificial intelligence (AI) stock that rocketed 855% over the last decade. Pershing's chief investment officer Ryan Israel said: "We felt that the company would be able to work through any slowdown in the cloud computing division Amazon Web Services, and we did not judge that tariffs would have a material impact on the earnings in the retail business." Interestingly, Ackman has a very concentrated portfolio that included fewer than a dozen stocks as of the first quarter. Chipmaker Nvidia was not one of those stocks. Amazon's market value exceeds $2 trillion today, but it could be much larger in a few years. The company has a strong presence in three growing industries, as detailed below: Not only does Amazon run the largest online marketplace in the U.S., but it also expects to gain market share this year. Domestic retail e-commerce sales are forecast to increase 8% annually through 2028, according to eMarketer. Amazon is the third-largest adtech company in the world and is rapidly taking share from industry leaders Google (part of Alphabet) and Meta Platforms. Retail ad spending is forecast to increase 17% annually in the U.S. through 2028, according to eMarketer. Amazon Web Services (AWS) is the largest public cloud operator, as measured by infrastructure and platform services spending. Cloud computing sales are forecast to grow at 20% annually through 2030, according to Grand View Research. Importantly, retail advertising and cloud services revenues not only are growing faster than online retail sales, but also have higher margins. That will make Amazon more profitable over time. But the company is also developing about 1,000 generative AI applications that will improve productivity and efficiency across its retail business, from front-end tasks like customer service to back-end tasks like coding. AWS is ideally positioned to monetize AI. It already operates the largest public cloud as measured by revenue and customers, but it has also introduced new products at all three layers of the computing stack. That includes custom chips for AI training and inference at the infrastructure layer, AI-model development tools like Bedrock at the platform layer, and AI applications like Amazon Q at the software layer. That three-tiered strategy is paying off. CEO Andy Jassy recently told analysts: "Our AI business has a multibillion-dollar annual revenue run rate," and "continues to grow triple-digit year-over-year percentages." Amazon shares soared 855% over the last decade as the company built strong positions in online retail, digital advertising, and cloud computing. And Wall Street is still predominantly bullish. Among the 71 analysts who follow the company, 96% rate the stock a buy, and the median target price is $235 per share, which implies 14% upside from the current share price of $205. Wall Street expects Amazon's earnings to increase at 10% annually through 2026. That makes the current price-to-earnings (P/E) ratio of 33 look somewhat expensive. But I think analysts are underestimating the company, as they have in the past -- Amazon topped the consensus earnings estimate by an average of 21% during the last six quarters. Long-term investors should feel comfortable buying a small position today. Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Trevor Jennewine has positions in Amazon and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Berkshire Hathaway, Brookfield, Brookfield Corporation, Howard Hughes, Meta Platforms, Nvidia, and Uber Technologies. The Motley Fool has a disclosure policy. Billionaire Bill Ackman Wants to Be the Next Warren Buffett, and He Is Buying an AI Stock Up 855% in 10 Years (Hint: Not Nvidia) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Sportsman's Warehouse (SPWH) Reports Q1: Everything You Need To Know Ahead Of Earnings
Outdoor specialty retailer Sportsman's Warehouse (NASDAQ:SPWH) will be reporting earnings tomorrow after market hours. Here's what investors should know. Sportsman's Warehouse beat analysts' revenue expectations by 3.6% last quarter, reporting revenues of $340.4 million, down 8.1% year on year. It was a stunning quarter for the company, with a solid beat of analysts' EPS estimates and an impressive beat of analysts' EBITDA estimates. Is Sportsman's Warehouse a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Sportsman's Warehouse's revenue to decline 2.5% year on year to $238.2 million, improving from the 8.7% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.47 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Sportsman's Warehouse has missed Wall Street's revenue estimates three times over the last two years. Looking at Sportsman's Warehouse's peers in the specialty retail segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Dick's delivered year-on-year revenue growth of 5.2%, beating analysts' expectations by 0.7%, and Ulta reported revenues up 4.5%, topping estimates by 1.9%. Dick's traded up 4.1% following the results while Ulta was also up 11.7%. Read our full analysis of Dick's results here and Ulta's results here. There has been positive sentiment among investors in the specialty retail segment, with share prices up 9.8% on average over the last month. Sportsman's Warehouse is up 17.8% during the same time and is heading into earnings with an average analyst price target of $2.90 (compared to the current share price of $1.99). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
